Merck, Inc.
Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)
- Conditions
- Reversal of Neuromuscular Blockade
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 344
- Registration Number
- NCT03346057
- Locations
- 🇺🇸
Mission Hospital - Memorial ( Site 1016), Asheville, North Carolina, United States
🇺🇸Cleveland Clin Foundation ( Site 1032), Cleveland, Ohio, United States
🇺🇸Hermann Drive Surgical Center ( Site 1021), Houston, Texas, United States
Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592) in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-120)
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2019-12-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 70
- Registration Number
- NCT03336502
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hosp CAMS&PUMC ( Site 0001), Tianjin, China
🇨🇳Shanghai General Hospital ( Site 0007), Shanghai, China
🇨🇳Peking University Third Hospital ( Site 0009), Beijing, China
Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001)
- First Posted Date
- 2017-10-31
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT03326986
- Locations
- 🇧🇪
Universitair Ziekenhuis Gent ( Site 0001), Gent, Belgium
Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)
- Conditions
- Renal Insufficiency
- Interventions
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 32
- Registration Number
- NCT03311841
- Locations
- 🇺🇸
Clinical Pharmacology of Miami ( Site 0001), Hialeah, Florida, United States
🇺🇸Orlando Clinical Research Center ( Site 0002), Orlando, Florida, United States
Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Biological: PembrolizumabOther: PlaceboBiological: Ipilimumab
- First Posted Date
- 2017-10-05
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 568
- Registration Number
- NCT03302234
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center ( Site 0016), Columbus, Ohio, United States
🇰🇷Severance Hospital Yonsei University Health System ( Site 2300), Seoul, Korea, Republic of
🇮🇪University Hospital Limerick ( Site 1403), Limerick, Ireland
Single-Dose Pharmacokinetics of MK-3866 in Participants With Hepatic Impairment (MK-3866-006)
- First Posted Date
- 2017-09-27
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 9
- Registration Number
- NCT03295266
- Locations
- 🇺🇸
Clinical Pharmacology of Miami ( Site 0001), Hialeah, Florida, United States
🇺🇸Orlando Clinical Research Center ( Site 0002), Orlando, Florida, United States
Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)
- Conditions
- Complicated Intra-abdominal InfectionComplicated Urinary Tract Infection
- Interventions
- Drug: Imipenem+Cilastatin/Relebactam
- First Posted Date
- 2017-09-26
- Last Posted Date
- 2021-02-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 83
- Registration Number
- NCT03293485
- Locations
- 🇯🇵
Nagoya Ekisaikai Hospital ( Site 1724), Nagoya, Aichi, Japan
🇯🇵Toyota Memorial Hospital ( Site 1708), Toyota, Aichi, Japan
🇯🇵Medical Corporation Chiyukai Fukuoka Shin Mizumaki Hospital ( Site 1710), Onga-gun, Fukuoka, Japan
Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)
- Conditions
- Squamous Cell Carcinoma
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2017-09-15
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 159
- Registration Number
- NCT03284424
- Locations
- 🇺🇸
Yale University ( Site 0365), New Haven, Connecticut, United States
🇺🇸Lombardi Comprehensive Cancer Center ( Site 0360), Washington, District of Columbia, United States
🇺🇸Sanford Cancer Center Oncology Clinic ( Site 0356), Sioux Falls, South Dakota, United States
Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)
- Conditions
- HIV-1 Infection
- Interventions
- Drug: Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
- First Posted Date
- 2017-09-05
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 123
- Registration Number
- NCT03272347
- Locations
- 🇺🇸
North Texas Infectious Diseases Consultants, PA ( Site 0103), Dallas, Texas, United States
🇺🇸Whitman Walker Clinic ( Site 0108), Washington, District of Columbia, United States
🇺🇸Orlando Immunology Center (OIC) ( Site 0105), Orlando, Florida, United States
Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2019-04-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 42
- Registration Number
- NCT03259087
- Locations
- 🇺🇸
Clinical Pharmacology of Miami ( Site 0001), Hialeah, Florida, United States
🇺🇸Orlando Clinical Research Center ( Site 0002), Orlando, Florida, United States